Dendreon (DNDN) Gets Takeover Buzz and a New Bull

June 13, 2012 12:47 PM EDT Send to a Friend
Get Alerts DNDN Hot Sheet
Trade DNDN Now!
The rumor mill has found Dendreon Corp. (Nasdaq: DNDN) again.

Shares of the embattled maker of cancer drug PROVENGE are jumping 7 percent Wednesday as traders snap-up the stock on renewed hopes for a buyout. Volume is on pace to be double the norm.

Dendreon newer CEO John Johnson has an M&A past, having successfully sold ImClone to Eli Lilly & attempted to sell Savient.

That being said, investors won't likely sell out for anything less than $20 per share. With shares in the toilet at $6-$7, this seems highly unlikely any time soon.

Also helping Dendreon today is a new Buy rating at Summer Street. The firm set an aggressive $18 price target, which suggests 166 percent upside from current levels.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Momentum Movers, Rumors

Add Your Comment